Zur Kurzanzeige

Efficacy of venlafaxine extended release in major depressive disorder patients

dc.contributor.authorLyndon, Gavin J.
dc.contributor.authorPrieto, Rita
dc.contributor.authorWajsbrot, Dalia B.
dc.contributor.authorAllgulander, Christer
dc.contributor.authorBandelow, Borwin
dc.date.accessioned2019-11-25T11:03:56Z
dc.date.available2019-11-25T11:03:56Z
dc.date.issued2019de
dc.relation.ISSN1473-5857de
dc.identifier.urihttp://resolver.sub.uni-goettingen.de/purl?gs-1/16708
dc.description.abstractEffects of baseline anxiety on the efficacy of venlafaxine extended release versus placebo were examined in a post hoc pooled subgroup analysis of 1573 patients enrolled in eight short-term studies of major depressive disorder. Anxiety subgroups were defined based on baseline 17-item Hamilton Rating Scale for Depression Item 10 score <3 (low) versus ≥3 (high). Change from baseline to final visit in Montgomery-Åsberg Depression Rating Scale total score and Montgomery-Åsberg Depression Rating Scale response and remission rates were analyzed. Change from baseline in Montgomery-Åsberg Depression Rating Scale total score and response and remission rates was significantly greater for venlafaxine extended release versus placebo in both low and high anxiety subgroups (all P < 0.0001). A statistically significant baseline anxiety by treatment interaction was observed for Montgomery-Åsberg Depression Rating Scale total score only (P = 0.0152). The adjusted mean change from baseline in Montgomery-Åsberg Depression Rating Scale total score was significantly greater in the high anxiety subgroup versus low anxiety subgroup for patients treated with venlafaxine extended release (-6.27 versus -3.89; P = 0.0440) but not placebo. These results support the efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms.de
dc.language.isoengde
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectanxiety, major depressive disorder, serotonin–norepinephrine reuptake inhibitor, treatment efficacy, venlafaxine extended releasede
dc.subject.ddc612
dc.titleEfficacy of venlafaxine extended release in major depressive disorder patientsde
dc.typejournalArticlede
dc.identifier.doi10.1097/YIC.0000000000000256
dc.type.versionpublishedVersionde
dc.relation.pISSN0268-1315
dc.bibliographicCitation.volume34de
dc.bibliographicCitation.issue3de
dc.bibliographicCitation.firstPage110de
dc.bibliographicCitation.lastPage118de
dc.type.subtypejournalArticle
dc.identifier.pmid30870236
dc.description.statuspeerReviewedde
dc.bibliographicCitation.journalInternational Clinical Psychopharmacologyde
dc.title.subtitleeffect of baseline anxiety symptom severity


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Nutzungslizenz für diese Dokumente:
openAccess